Albert Dme Osterhaus

List of Publications by Year
in descending order

265 papers	30,937 citations	11651 70 h-index	4885 168 g-index
303 all docs	303 docs citations	303 times ranked	28971 citing authors

#	Article	IF	Citations
1	Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England Journal of Medicine, 2012, 367, 1814-1820.	27.0	4,688
2	Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976.	27.0	3,971
3	A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Medicine, 2001, 7, 719-724.	30.7	1,821
4	Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, The, 1998, 351, 472-477.	13.7	1,266
5	The Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 349, 2431-2441.	27.0	1,133
6	Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, The, 2003, 362, 263-270.	13.7	956
7	Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet, The, 2004, 363, 587-593.	13.7	731
8	Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infectious Diseases, The, 2013, 13, 859-866.	9.1	616
9	Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals. American Journal of Pathology, 2007, 171, 1215-1223.	3.8	473
10	Clearance of influenza virus from the lung depends on migratory langerin+CD11bâ^' but not plasmacytoid dendritic cells. Journal of Experimental Medicine, 2008, 205, 1621-1634.	8.5	419
11	Avian Influenza H5N1 in Tigers and Leopards. Emerging Infectious Diseases, 2004, 10, 2189-2191.	4.3	405
12	Analysis of the Genomic Sequence of a Human Metapneumovirus. Virology, 2002, 295, 119-132.	2.4	382
13	Avian H5N1 Influenza in Cats. Science, 2004, 306, 241-241.	12.6	374
14	Wild Ducks as Long-Distance Vectors of Highly Pathogenic Avian Influenza Virus (H5N1). Emerging Infectious Diseases, 2008, 14, 600-607.	4.3	374
15	Antigenic and Genetic Variability of Human Metapneumoviruses. Emerging Infectious Diseases, 2004, 10, 658-666.	4.3	329
16	Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virusâ€"infected mice. Journal of Experimental Medicine, 2009, 206, 2339-2349.	8.5	311
17	Respiratory Picornaviruses and Respiratory Syncytial Virus as Causative Agents of Acute Expiratory Wheezing in Children. Emerging Infectious Diseases, 2004, 10, 1095-1101.	4.3	298
18	Metapneumovirus and acute wheezing in children. Lancet, The, 2002, 360, 1393-1394.	13.7	271

#	Article	IF	Citations
19	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, The, 2004, 363, 2139-2141.	13.7	252
20	Influenza A Virus (H5N1) Infection in Cats Causes Systemic Disease with Potential Novel Routes of Virus Spread within and between Hosts. American Journal of Pathology, 2006, 168, 176-183.	3.8	252
21	Surveillance of Influenza Virus A in Migratory Waterfowl in Northern Europe. Emerging Infectious Diseases, 2007, 13, 404-411.	4.3	214
22	Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine, 2008, 26, D31-D34.	3.8	208
23	Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology, 2000, 61, 94-99.	5.0	200
24	Dengue viruses cluster antigenically but not as discrete serotypes. Science, 2015, 349, 1338-1343.	12.6	195
25	Mallards and Highly Pathogenic Avian Influenza Ancestral Viruses, Northern Europe. Emerging Infectious Diseases, 2005, 11, 1545-1551.	4.3	187
26	Mass Die-Off of Caspian Seals Caused by Canine Distemper Virus. Emerging Infectious Diseases, 2000, 6, 637-639.	4.3	178
27	Effects of influenza A virus infection on migrating mallard ducks. Proceedings of the Royal Society B: Biological Sciences, 2009, 276, 1029-1036.	2.6	174
28	Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Research, 2004, 103, 155-161.	2.2	171
29	MERS: emergence of a novel human coronavirus. Current Opinion in Virology, 2014, 5, 58-62.	5.4	170
30	Response to Imported Case of Marburg Hemorrhagic Fever, the Netherlands. Emerging Infectious Diseases, 2009, 15, 1171-1175.	4.3	165
31	Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014. Emerging Infectious Diseases, 2014, 20, 1339-42.	4.3	164
32	Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine, 2001, 19, 3700-3709.	3.8	161
33	Novel Hepatitis E Virus in Ferrets, the Netherlands. Emerging Infectious Diseases, 2012, 18, 1369-1370.	4.3	158
34	Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. Journal of Clinical Virology, 2013, 58, 629-634.	3.1	157
35	Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine. PLoS ONE, 2008, 3, e1401.	2.5	148
36	Seasonal and Pandemic Human Influenza Viruses Attach Better to Human Upper Respiratory Tract Epithelium than Avian Influenza Viruses. American Journal of Pathology, 2010, 176, 1614-1618.	3.8	146

#	Article	IF	Citations
37	Experimental Human Metapneumovirus Infection of Cynomolgus Macaques (Macaca fascicularis) Results in Virus Replication in Ciliated Epithelial Cells and Pneumocytes with Associated Lesions throughout the Respiratory Tract. American Journal of Pathology, 2004, 164, 1893-1900.	3.8	145
38	Another Phocine Distemper Outbreak in Europe. Science, 2002, 297, 209-209.	12.6	138
39	Hepatitis E Virus Infection among Solid Organ Transplant Recipients, the Netherlands. Emerging Infectious Diseases, 2012, 18, 869-872.	4.3	135
40	Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine, 2013, 31, 6030-6033.	3.8	135
41	Impact of human metapneumovirus in childhood: Comparison with respiratory syncytial virus and influenza viruses. Journal of Medical Virology, 2005, 75, 101-104.	5.0	134
42	ISCOM technology-based Matrix Mâ„¢ adjuvant: success in future vaccines relies on formulation. Expert Review of Vaccines, 2011, 10, 401-403.	4.4	128
43	Canine distemper virus â€" A morbillivirus in search of new hosts?. Trends in Microbiology, 1997, 5, 120-124.	7.7	127
44	Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine, 2014, 32, 5975-5982.	3.8	121
45	Interferon-Î³ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481.	2.4	120
46	Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatric Allergy and Immunology, 2003, 14, 363-370.	2.6	119
47	Current and future applications of dried blood spots in viral disease management. Antiviral Research, 2012, 93, 309-321.	4.1	115
48	Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Current Opinion in Biotechnology, 2007, 18, 529-536.	6.6	111
49	Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes and Infection, 2002, 4, 1209-1215.	1.9	110
50	Adaptive pathways of zoonotic influenza viruses: From exposure to establishment in humans. Vaccine, 2012, 30, 4419-4434.	3.8	109
51	AIDS, Avian flu, SARS, MERS, Ebola, Zikaâ€¦ what next?. Vaccine, 2017, 35, 4470-4474.	3.8	109
52	Human metapneumovirus in the community. Lancet, The, 2003, 361, 890-891.	13.7	104
53	Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. Journal of Medical Virology, 2005, 76, 547-552.	5.0	103
54	Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. International Journal of Antimicrobial Agents, 2014, 44, 528-532.	2.5	103

#	Article	IF	Citations
55	Pathogenesis of Influenza A/H5N1 Virus Infection in Ferrets Differs between Intranasal and Intratracheal Routes of Inoculation. American Journal of Pathology, 2011, 179, 30-36.	3.8	95
56	A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clinical Immunology, 2012, 142, 252-268.	3.2	93
57	Global Assessment of Resistance to Neuraminidase Inhibitors, 2008â€“2011: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, 2013, 56, 1197-1205.	5.8	93
58	Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets. PLoS Pathogens, 2013, 9, e1003343.	4.7	92
59	Avian Influenza A(H10N7) Virusâ€“Associated Mass Deaths among Harbor Seals. Emerging Infectious Diseases, 2015, 21, 720-722.	4.3	92
60	Antigen Loading of MHC Class I Molecules in the Endocytic Tract. Traffic, 2001, 2, 124-137.	2.7	91
61	West Nile Virus: Immunity and Pathogenesis. Viruses, 2011, 3, 811-828.	3.3	91
62	Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Review of Vaccines, 2010, 9, 59-72.	4.4	85
63	A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virology Journal, 2010, 7, 146.	3.4	85
64	Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine, 2017, 35, 5095-5101.	3.8	84
65	A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine, 2005, 23, 1657-1667.	3.8	79
66	Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. Journal of Medical Virology, 2006, 78, 1609-1615.	5.0	79
67	Morbillivirus in monk seal mass mortality. Nature, 1997, 388, 838-839.	27.8	78
68	Human herpes simplex virus keratitis: the pathogenesis revisited. Ocular Immunology and Inflammation, 2004, 12, 255-285.	1.8	77
69	Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human coronaviruses. Current Opinion in Infectious Diseases, 2005, 18, 141-146.	3.1	77
70	Recurring Influenza B Virus Infections in Seals. Emerging Infectious Diseases, 2013, 19, 511-512.	4.3	74
71	Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza and Other Respiratory Viruses, 2018, 12, 267-278.	3.4	73
72	Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010â€“2011. Emerging Infectious Diseases, 2013, 19, .	4.3	72

#	Article	IF	Citations
73	Emerging viral infections in a rapidly changing world. Current Opinion in Biotechnology, 2003, 14, 641-646.	6.6	71
74	Relative immunocompetence of the newborn harbour seal, Phoca vitulina. Veterinary Immunology and Immunopathology, 1994, 42, 331-348.	1.2	70
75	An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine, 2004, 22, 3035-3044.	3.8	69
76	Influenza Virus Resistance to Antiviral Therapy. Advances in Pharmacology, 2013, 67, 217-246.	2.0	69
77	Possible Increased Pathogenicity of Pandemic (H1N1) 2009 Influenza Virus upon Reassortment. Emerging Infectious Diseases, 2011, 17, 200-208.	4.3	67
78	Highly Pathogenic Avian Influenza Virus (H5N1) Infection in Red Foxes Fed Infected Bird Carcasses. Emerging Infectious Diseases, 2008, 14, 1835-1841.	4.3	66
79	Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. Journal of Medical Virology, 2003, 70, 91-98.	5.0	64
80	Towards improved influenza A virus surveillance in migrating birds. Vaccine, 2006, 24, 6729-6733.	3.8	64
81	Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 78-85.	0.6	63
82	DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-Î± and TNF-Î±. Virus Research, 2008, 135, 64-71.	2.2	62
83	On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals, 2009, 37, 216-221.	1.4	62
84	Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine, 2008, 26, 153-157.	3.8	60
85	Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine, 2009, 27, 6363-6365.	3.8	58
86	Viral metagenomic analysis of feces of wild small carnivores. Virology Journal, 2014, 11, 89.	3.4	57
87	Comparative study of different methods to genotype hepatitis C virus type 6 variants. Journal of Virological Methods, 2003, 109, 195-201.	2.1	56
88	Catastrophes after crossing species barriers. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 791-793.	4.0	55
89	Measles vaccination of macaques by dry powder inhalation. Vaccine, 2007, 25, 1183-1190.	3.8	55
90	Association between high nasopharyngeal viral load and disease severity in children with human metapneumovirus infection. Journal of Clinical Virology, 2008, 42, 286-290.	3.1	53

#	Article	IF	Citations
91	Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. Journal of Medical Virology, 2004, 72, 445-450.	5.0	52
92	Novel Avian-Origin Influenza A (H7N9) Virus Attaches to Epithelium in Both Upper and Lower Respiratory Tract of Humans. American Journal of Pathology, 2013, 183, 1137-1143.	3.8	52
93	Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine, 2007, 25, 8518-8528.	3.8	51
94	Towards universal influenza vaccines?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2766-2773.	4.0	51
95	Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable â€“ epidemiology, diagnostics and treatment. Critical Reviews in Microbiology, 2013, 39, 26-42.	6.1	51
96	Global task force for influenza. Nature, 2005, 435, 419-420.	27.8	50
97	VÎ³9VÎ´2 T cells recovered from eyes of patients with BehÃ§et's disease recognize non-peptide prenyl pyrophosphate antigens. Journal of Neuroimmunology, 2002, 130, 46-54.	2.3	49
98	Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. Journal of Clinical Virology, 2004, 29, 92-94.	3.1	49
99	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016, 12, 1-18.	3.3	49
100	The Application of Genomics to Emerging Zoonotic Viral Diseases. PLoS Pathogens, 2009, 5, e1000557.	4.7	49
101	A determinant of feline immunodeficiency virus involved in Crandell feline kidney cell tropism. Veterinary Immunology and Immunopathology, 1995, 46, 61-69.	1.2	48
102	Quantitative proteome profiling of respiratory virus-infected lung epithelial cells. Journal of Proteomics, 2010, 73, 1680-1693.	2.4	48
103	Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. Journal of Clinical Virology, 2012, 53, 38-42.	3.1	48
104	Vector-based genetically modified vaccines: Exploiting Jennerâ€™s legacy. Vaccine, 2016, 34, 6436-6448.	3.8	48
105	Coronaviruses and their therapy. Antiviral Research, 2006, 71, 397-403.	4.1	47
106	Genetic Characterization of HPAI (H5N1) Viruses from Poultry and Wild Vultures, Burkina Faso. Emerging Infectious Diseases, 2007, 13, 611-613.	4.3	47
107	Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine, 2004, 22, 915-922.	3.8	45
108	Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine, 2008, 26, 4224-4230.	3.8	45

#	Article	IF	Citations
109	Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. Blood Advances, 2020, 4, 2967-2978.	5.2	45
110	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	4.1	43
111	Highly pathogenic avian influenza (H7N7): Vaccination of zoo birds and transmission to non-poultry species. Vaccine, 2005, 23, 5743-5750.	3.8	43
112	The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine, 2002, 20, 2011-2015.	3.8	42
113	Feline friend or potential foe?. Nature, 2006, 440, 741-742.	27.8	42
114	Rinderpest eradication: lessons for measles eradication?. Current Opinion in Virology, 2012, 2, 330-334.	5.4	42
115	Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. Viruses, 2016, 8, 168.	3.3	42
116	An improved plaque reduction virus neutralization assay for human metapneumovirus. Journal of Virological Methods, 2007, 143, 169-174.	2.1	41
117	Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin, 2009, 5, 126-135.	2.4	41
118	Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections. Journal of Innate Immunity, 2013, 5, 197-208.	3.8	40
119	No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. Journal of Clinical Virology, 2010, 49, 26-31.	3.1	39
120	Genogroup I and II Picobirnaviruses in Respiratory Tracts of Pigs. Emerging Infectious Diseases, 2011, 17, 2328-2330.	4.3	39
121	Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. Microbes and Infection, 2007, 9, 940-946.	1.9	38
122	Longitudinal study on oral shedding of herpes simplex virus 1 and varicellaâ€zoster virus in individuals infected with HIV. Journal of Medical Virology, 2013, 85, 1669-1677.	5.0	37
123	Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine, 1998, 16, 1479-1481.	3.8	36
124	Mounting evidence for the presence of influenza A virus in the avifauna of the Antarctic region. Antarctic Science, 2006, 18, 353-356.	0.9	36
125	Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine, 2007, 25, 3800-3808.	3.8	36
126	Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. Journal of Virological Methods, 2015, 217, 55-63.	2.1	36

#	Article	IF	Citations
127	Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. Journal of Virological Methods, 1998, 71, 35-44.	2.1	35
128	Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine, 2000, 19, 42-53.	3.8	35
129	Stage-structured transmission of phocine distemper virus in the Dutch 2002 outbreak. Proceedings of the Royal Society B: Biological Sciences, 2009, 276, 2469-2476.	2.6	35
130	Influenza viruses. Human Vaccines and Immunotherapeutics, 2012, 8, 7-16.	3.3	35
131	Annual influenza vaccination affects the development of heterosubtypic immunity. Vaccine, 2012, 30, 7407-7410.	3.8	35
132	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Science Immunology, 2022, 7, eabp9312.	11.9	35
133	Aerosol measles vaccination in macaques: Preclinical studies of immune responses and safety. Vaccine, 2006, 24, 6424-6436.	3.8	34
134	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154.	2.4	34
135	Pre- or post-pandemic influenza vaccine?. Vaccine, 2007, 25, 4983-4984.	3.8	34
136	Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA. Journal of Virological Methods, 2013, 194, 146-153.	2.1	34
137	Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. Journal of Clinical Virology, 2013, 57, 215-221.	3.1	34
138	Host-specific exposure and fatal neurologic disease in wild raptors from highly pathogenic avian influenza virus H5N1 during the 2006 outbreak in Germany. Veterinary Research, 2015, 46, 24.	3.0	34
139	RSV-induced bronchiolitis but not upper respiratory tract infection is accompanied by an increased nasal IL-18 response. Journal of Medical Virology, 2003, 71, 290-297.	5.0	33
140	Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Research, 2007, 129, 175-181.	2.2	33
141	Highly Pathogenic Avian Influenza Virus H7N7 Isolated From a Fatal Human Case Causes Respiratory Disease in Cats but Does Not Spread Systemically. American Journal of Pathology, 2010, 177, 2185-2190.	3.8	33
142	Picobirnaviruses in the Human Respiratory Tract. Emerging Infectious Diseases, 2012, 18, 1538-1539.	4.3	33
143	Wild Birds and Increased Transmission of Highly Pathogenic Avian Influenza (H5N1) among Poultry, Thailand. Emerging Infectious Diseases, 2011, 17, 1016-1022.	4.3	33
144	Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine, 2004, 22, 923-926.	3.8	32

#	Article	IF	Citations
145	Experimental Pandemic (H1N1) 2009 Virus Infection of Cats. Emerging Infectious Diseases, 2010, 16, 1745-1747.	4.3	32
146	Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009â€“2010. Antiviral Research, 2011, 92, 81-89.	4.1	32
147	Molecular Assays for Quantitative and Qualitative Detection of Influenza Virus and Oseltamivir Resistance Mutations. Journal of Molecular Diagnostics, 2013, 15, 347-354.	2.8	32
148	Transmission of morbilliviruses within and among marine mammal species. Current Opinion in Virology, 2018, 28, 133-141.	5.4	32
149	Efficacy of a live attenuated tetravalent candidate dengue vaccine in naÃ¨ve and previously infected cynomolgus macaques. Vaccine, 2007, 25, 5409-5416.	3.8	31
150	Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infectious Diseases, 2007, 7, 22.	2.9	31
151	Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infectious Diseases, 2015, 15, 371.	2.9	31
152	Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses. Emerging Infectious Diseases, 2015, 21, 1357-1365.	4.3	31
153	Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiology, 2014, 14, 134.	3.3	30
154	Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene. Vaccine, 2006, 24, 6647-6650.	3.8	29
155	Does influenza vaccination exacerbate asthma in children?. Vaccine, 2004, 23, 91-96.	3.8	28
156	Pigs, Poultry, and Pandemic Influenza: How Zoonotic Pathogens Threaten Human Health. Advances in Experimental Medicine and Biology, 2012, 719, 59-66.	1.6	28
157	Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh. Emerging Infectious Diseases, 2012, 18, 1192-1195.	4.3	28
158	In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine, 2000, 18, 2482-2493.	3.8	27
159	Vaccination against measles: a neverending story. Expert Review of Vaccines, 2002, 1, 151-159.	4.4	27
160	Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine, 2008, 26, 3735-3741.	3.8	27
161	Prevalence of phocine distemper virus specific antibodies: bracing for the next seal epizootic in north-western Europe. Emerging Microbes and Infections, 2013, 2, 1-5.	6.5	27
162	Integration of Vitamin A Supplementation with the Expanded Program on Immunization Does Not Affect Seroconversion to Oral Poliovirus Vaccine in Infants. Journal of Nutrition, 1999, 129, 2203-2205.	2.9	26

#	Article	IF	Citations
163	Preparing the outbreak assistance laboratory network in the Netherlands for the detection of the influenza virus A(H1N1) variant. Journal of Clinical Virology, 2009, 45, 179-184.	3.1	26
164	Systemic varicella zoster virus reactive effector memory Tâ€cells impaired in the elderly and in kidney transplant recipients. Journal of Medical Virology, 2012, 84, 2018-2025.	5.0	26
165	High prevalence of influenza A virus in ducks caught during spring migration through Sweden. Vaccine, 2006, 24, 6734-6735.	3.8	25
166	Virus discovery: one step beyond. Current Opinion in Virology, 2013, 3, e1-e6.	5.4	25
167	Paramyxovirus infections in ex vivo lung slice cultures of different host species. Journal of Virological Methods, 2013, 193, 159-165.	2.1	25
168	Influenza: from zoonosis to pandemic. ERJ Open Research, 2016, 2, 00013-2016.	2.6	25
169	Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses. Emerging Infectious Diseases, 2015, 21, 1357-1365.	4.3	25
170	Rapid sequencing of the non-coding regions of influenza A virus. Journal of Virological Methods, 2007, 139, 85-89.	2.1	24
171	Quantifying the risk of pandemic influenza virus evolution by mutation and re-assortment. Vaccine, 2015, 33, 6955-6966.	3.8	24
172	New clues to the emergence of flu pandemics. Nature Medicine, 1998, 4, 1122-1123.	30.7	23
173	Coronavirus HKU1 in an Italian pre-term infant with bronchiolitis. Journal of Clinical Virology, 2007, 38, 251-253.	3.1	23
174	Measles vaccination: new strategies and formulations. Expert Review of Vaccines, 2008, 7, 1215-1223.	4.4	23
175	Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naÃ¯ve ferrets. Vaccine, 2011, 29, 2120-2126.	3.8	23
176	Virus characterization and discovery in formalin-fixed paraffin-embedded tissues. Journal of Virological Methods, 2015, 214, 54-59.	2.1	23
177	Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine, 2002, 20, 2022-2026.	3.8	22
178	Report of the fourth meeting on â€˜Influenza vaccines that induce broad spectrum and long-lasting immune responsesâ€™, World Health Organization and Wellcome Trust, London, United Kingdom, 9â€“10 November 2009. Vaccine, 2010, 28, 3875-3882.	3.8	22
179	Hyperferritinemia is a potential marker of chronic chikungunya: A retrospective study on the Island of CuraÃ§ao during the 2014â€“2015 outbreak. Journal of Clinical Virology, 2017, 86, 31-38.	3.1	22
180	Phocine Distemper Outbreak, the Netherlands, 2002. Emerging Infectious Diseases, 2005, 11, 1945-1948.	4.3	21

#	Article	IF	Citations
181	Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies. Vaccine, 2011, 29, 3424-3430.	3.8	21
182	Accumulation features of trace elements in mass-stranded harbor seals (Phoca vitulina) in the North Sea coast in 2002: The body distribution and association with growth and nutrition status. Marine Pollution Bulletin, 2011, 62, 963-975.	5.0	21
183	Comparison of Different In Situ Hybridization Techniques for the Detection of Various RNA and DNA Viruses. Viruses, 2018, 10, 384.	3.3	21
184	Influenza A and B Virus Attachment to Respiratory Tract in Marine Mammals. Emerging Infectious Diseases, 2012, 18, 817-820.	4.3	20
185	Hemagglutinin Traits Determine Transmission of Avian A/H10N7 Influenza Virus between Mammals. Cell Host and Microbe, 2020, 28, 602-613.e7.	11.0	20
186	Comprehensive analysis of the intracellular metabolism of antiretroviral nucleosides and nucleotides using liquid chromatographyâ€“tandem mass spectrometry and method improvement by using ultra performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2772-2782.	2.3	19
187	Transgenic Mice Expressing Human HLA and CD8 Molecules Generate HLA-Restricted Measles Virus Cytotoxic T Lymphocytes of the Same Specificity as Humans with Natural Measles Virus Infection. Virology, 2000, 275, 286-293.	2.4	18
188	DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine, 2002, 20, 2045-2052.	3.8	18
189	Advances in influenza vaccination. F1000prime Reports, 2014, 6, 47.	5.9	18
190	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. Virus Research, 2012, 169, 301-305.	2.2	17
191	Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity. Journal of Infection, 2015, 71, 437-446.	3.3	17
192	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Frontiers in Medicine, 2021, 8, 749588.	2.6	17
193	Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins. Microbes and Infection, 2003, 5, 379-385.	1.9	16
194	Characterization of the varicella zoster virus (VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis. Experimental Eye Research, 2006, 83, 69-75.	2.6	16
195	Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. Journal of Medical Virology, 2016, 88, 1035-1043.	5.0	16
196	Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Vaccine, 2016, 34, 1915-1926.	3.8	16
197	An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells. Virus Research, 2007, 126, 282-287.	2.2	15
198	Unraveling the complexities of the interferon response during SARS-CoV infection. Future Virology, 2009, 4, 71-78.	1.8	15

#	Article	IF	Citations
199	Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine, 2011, 29, 2092-2099.	3.8	15
200	Intranasally administered Endocineâ„¢ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Vaccine, 2014, 32, 3307-3315.	3.8	15
201	Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. Vaccine, 2002, 21, 155-157.	3.8	14
202	â€œFilovirusesâ€• a real pandemic threat?. EMBO Molecular Medicine, 2009, 1, 10-18.	6.9	14
203	New Respiratory Viruses of Humans. Pediatric Infectious Disease Journal, 2008, 27, S71-S74.	2.0	13
204	Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine, 2011, 29, 9265-9270.	3.8	13
205	Pediatric influenza vaccination: understanding the T-cell response. Expert Review of Vaccines, 2012, 11, 963-971.	4.4	13
206	Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine, 2014, 32, 5614-5623.	3.8	13
207	Pathogenesis of Infection with 2009 Pandemic H1N1 Influenza Virus in Isogenic Guinea Pigs after Intranasal or Intratracheal Inoculation. American Journal of Pathology, 2015, 185, 643-650.	3.8	13
208	Acquisition and Clearance of Perianal Human Papillomavirus Infection in Relation to HIVâ€positivity in Men Who Have Sex with Men in the Netherlands. Acta Dermato-Venereologica, 2005, 85, 437-443.	1.3	12
209	Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine, 2009, 27, 5735-5739.	3.8	12
210	Targets for the Induction of Protective Immunity Against Influenza A Viruses. Viruses, 2010, 2, 166-188.	3.3	12
211	Experimental infection of highly pathogenic avian influenza virus H5N1 in black-headed gulls (Chroicocephalus ridibundus). Veterinary Research, 2014, 45, 84.	3.0	12
212	In Vitro and in Vivo Evaluation of Mutations in the NS Region of Lineage 2 West Nile Virus Associated with Neuroinvasiveness in a Mammalian Model. Viruses, 2016, 8, 49.	3.3	12
213	Validation of an HIV-1 inactivation protocol that is compatible with intracellular drug analysis by mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 38-44.	2.3	11
214	Periodic global One Health threats update. One Health, 2016, 2, 1-7.	3.4	11
215	In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine, 2001, 20, 249-261.	3.8	10
216	Epidemiology of Avian Influenza. Monographs in Virology, 2008, , 1-10.	0.6	10

#	Article	IF	Citations
217	Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model. Vaccine, 2012, 30, 7391-7394.	3.8	10
218	Age distribution of cases caused by different influenza viruses. Lancet Infectious Diseases, The, 2013, 13, 646-647.	9.1	10
219	DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. Vaccine, 2015, 33, 2922-2929.	3.8	10
220	Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine, 2015, 33, 4349-4358.	3.8	10
221	Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro. Virus Research, 2015, 195, 43-46.	2.2	10
222	Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 155-164.	1.6	10
223	Intrahost evolution of envelope glycoprotein and OrfA sequences after experimental infection of cats with a molecular clone and a biological isolate of feline immunodeficiency virus. Virus Research, 2008, 137, 24-32.	2.2	9
224	Pathogenicity and tissue tropism of currently circulating highly pathogenic avian influenza A virus (H5N1; clade 2.3.2) in tufted ducks (Aythya fuligula). Veterinary Microbiology, 2015, 180, 273-280.	1.9	9
225	Virus detection in high-throughput sequencing data without a reference genome of the host. Infection, Genetics and Evolution, 2018, 66, 180-187.	2.3	9
226	T Cell Responses to Respiratory Syncytial Virus Fusion and Attachment Proteins in Human Peripheral Blood Mononuclear Cells. Viral Immunology, 2006, 19, 669-678.	1.3	8
227	Vaccines against seasonal and avian influenza: Recent advances. Vaccine, 2008, 26, D1-D2.	3.8	8
228	The ins and outs of universal childhood influenza vaccination. Future Microbiology, 2011, 6, 1171-1184.	2.0	8
229	Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets. Vaccine, 2012, 30, 5073-5080.	3.8	8
230	Early divergence of Th1 and Th2 transcriptomes involves a small core response and sets of transiently expressed genes. European Journal of Immunology, 2013, 43, 1074-1084.	2.9	8
231	A candidate phocid herpesvirus vaccine that provides protection against feline herpesvirus infection. Vaccine, 2001, 20, 943-948.	3.8	7
232	The choice of antigen for therapeutic immunization against AIDS. Trends in Immunology, 2002, 23, 478-479.	6.8	7
233	Virogenomics: the virusâ€“host interaction revisited. Current Opinion in Microbiology, 2008, 11, 461-466.	5.1	7
234	HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. Aids, 2013, 27, 2679-2689.	2.2	7

#	Article	IF	Citations
235	Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness. Disaster Medicine and Public Health Preparedness, 2016, 10, 644-648.	1.3	7
236	Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model. Viruses, 2018, 10, 18.	3.3	7
237	Mannitol treatment is not effective in therapy of rabies virus infection in mice. Vaccine, 2019, 37, 4710-4714.	3.8	7
238	Immunogenicity and efficacy of recombinant subunit vaccines against phocid herpesvirus type 1. Vaccine, 2003, 21, 2433-2440.	3.8	6
239	Why should influenza be a public health priority?. Vaccine, 2015, 33, 7022-7025.	3.8	6
240	Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef. Journal of Virological Methods, 2002, 99, 115-121.	2.1	5
241	RNA secondary structures in the proximal 3â€²UTR of Indonesian Dengue 1 virus strains. Virus Research, 2009, 142, 213-216.	2.2	5
242	Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine. Vaccine, 2010, 28, 4970-4976.	3.8	5
243	Vaccination strategies to protect children against seasonal and pandemic influenza. Vaccine, 2011, 29, 7551-7553.	3.8	5
244	Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus. Vaccine, 2015, 33, 6977-6982.	3.8	5
245	In vitro and in vivo replication of seal gammaherpesviruses in cells of multiple species. Microbes and Infection, 2007, 9, 40-46.	1.9	4
246	CCR5-Restricted HIV Type 2 Variants from Long-Term Aviremic Individuals Are Less Sensitive to Inhibition byÎ²-Chemokines Than Low Pathogenic HIV Type 1 Variants. AIDS Research and Human Retroviruses, 2008, 24, 473-484.	1.1	4
247	Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats. Vaccine, 2008, 26, 2553-2561.	3.8	3
248	Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA. Veterinary Immunology and Immunopathology, 2008, 126, 332-338.	1.2	3
249	Pandemic preparedness planning in peacetime: what is missing?. One Health Outlook, 2020, 2, 19.	3.4	3
250	SARS. , 2009, , 671-683.		2
251	Pandemics: is hoping for the best enough?. EMBO Reports, 2010, 11, 142-142.	4.5	2
252	Emerging Viral Infections. , 2013, , 1142-1154.		2

#	Article	IF	Citations
253	COVID-19 vaccination and critical care capacity: Perilous months ahead. Vaccine, 2021, 39, 2183-2186.	3.8	2
254	Cross-reactive immunity potentially drives global oscillation and opposed alternation patterns of seasonal influenza A viruses. Scientific Reports, 2022, 12, .	3.3	2
255	Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 2578-2583.	3.3	1
256	TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 759-772.	3.3	1
257	Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. , 2000, 61, 94.		1
258	Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice.. Blood, 2004, 104, 47-47.	1.4	1
259	HIV and Smallpox. Science, 2005, 308, 1258b-1259b.	12.6	0
260	Appendix: Representative Compounds with Inhibitory Activity Against SARS CoV or Other CoVs in vitro. , 2008, , 255-256.		0
261	Colour Plate. , 2008, , I-IV.		0
262	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 2. Future Virology, 2011, 6, 1283-1288.	1.8	0
263	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 1. Future Virology, 2011, 6, 1155-1160.	1.8	0
264	Severe acute respiratory syndrome (SARS) vaccines. , 2008, , 1301-1306.		0
265	Influenza from a One Health Perspective: Infection by a Highly Versatile Virus. , 2015, , 455-486.		0